Failure-mode evidence depth
Coverage meters, not risk scores. Open the linked section to read direction.Stack
Reviewed sequence, HELM, or SMILES representation used to interpret this peptide identity.
Molecular graph, chemical representation, 3D references, and covalent topology when available.
Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity.
Product-level route, label, and clinical context that frames peptide-level evidence.
What evidence describes systemic exposure or absorption?
What is known about distribution, binding, permeability, or barrier crossing?
What evidence describes clearance or persistence?
Cross-domain evidence distribution, traceability, and measurement-level detail for this peptide.
Reference-level support for checking reported names, sequence notation, and peptide identity agreement.
Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.
Are molecular graph, topology, or 3D coordinates available?
Can basic developability descriptors be computed?
How stable is the peptide in biological matrices or protease systems?
What safety, toxicity, or tolerability evidence is attached?
Not availablePolymer notation for modified peptide representation when available.
Not availableChemical graph string used for atom-level 2D depiction when available.
Not availableA reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.
A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.
No disulfide, staple, coordination, other cross-link, or residue-level modification annotation is attached to this peptide in the current release.
Interpretation: A 2D graph describes connectivity, not conformation. A 3D reference describes one coordinate model or solved state, not the full ensemble. ADMET interpretation should account for peptidoform, topology, and assay context together.
3 Ro5 violations · MW 1,816.72 Da
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Bioavailability, AUC, Cmax, and Tmax evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | Observation Due to its poor oral bioavailability, it is available only in an intravenous formulation | Reported | PepTherDia curated product PK field | Route: IV · 84 · Dalbavancin · exact product name match · exact or normalized match | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 848000 ng*h/mL | Comparable | AUC (0-infinity) in ICR mouse at 20 mg/kg, ip · mouse | Route: ip · area under curve · AUC· AUC (0-infinity) in ICR mouse at 20 mg/kg, ip · Exact ChEMBL pref... | Open |
| 2 | 1071000 ng*h/mL | Comparable | AUC (0-infinity) in ICR mouse at 20 mg/kg, iv · mouse | Route: iv · area under curve · AUC· AUC (0-infinity) in ICR mouse at 20 mg/kg, iv · Exact ChEMBL pref... | Open |
| 3 | 176000 ng*h/mL | Comparable | AUC (0-infinity) in ICR mouse at 5 mg/kg, ip · mouse | Route: ip · area under curve · AUC· AUC (0-infinity) in ICR mouse at 5 mg/kg, ip · Exact ChEMBL pref... | Open |
| 4 | 200000 ng*h/mL | Comparable | AUC (0-infinity) in ICR mouse at 5 mg/kg, iv · mouse | Route: iv · area under curve · AUC· AUC (0-infinity) in ICR mouse at 5 mg/kg, iv · Exact ChEMBL pref... | Open |
| 5 | 756000 ng*h/mL | Comparable | AUC in patient with skin and soft tissue infections at 1000 mg, iv after 7 days · human | Route: iv · area under curve · AUC· AUC in patient with skin and soft tissue infections at 1000 mg, i... | Open |
| 6 | 3185 mg*h/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Dalbavancin· 12.3 Pharmacokinetics · dalbavancin table auc 0 24 1000mg · Dalbavancin Phar... | Open |
| 7 | 4837 mg*h/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Dalbavancin· 12.3 Pharmacokinetics · dalbavancin table auc 0 24 1500mg · Dalbavancin Phar... | Open |
| 8 | 11160 mg*h/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Dalbavancin· 12.3 Pharmacokinetics · dalbavancin table auc 0 day7 single dose · Dalbavanc... | Open |
| 9 | 23443 mg*h/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Dalbavancin· 12.3 Pharmacokinetics · dalbavancin table auc 0 inf single dose · Dalbavanci... | Open |
| 10 | Observation mean AUC 0-336 hrs was unchanged in subjects with mild hepatic impairment compared to subjects with normal hepatic function; however, the mean AUC 0-336 hrs decreased 28% and 31% in subjects with moderate and severe hepatic impairment respectively, compared to subjects with normal hepatic function. | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Dalbavancin· 12.3 Pharmacokinetics · dalbavancin hepatic impairment auc change text · mea... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 39246.55 nM | Comparable | Cmax in ICR mouse at 20 mg/kg, ip after 2 hrs · mouse | Route: ip · max concentration · Cmax· Cmax in ICR mouse at 20 mg/kg, ip after 2 hrs · Exact ChEMBL pr... | Open |
| 2 | 8366.73 nM | Comparable | Cmax in ICR mouse at 5 mg/kg, ip after 2 hrs · mouse | Route: ip · max concentration · Cmax· Cmax in ICR mouse at 5 mg/kg, ip after 2 hrs · Exact ChEMBL pre... | Open |
| 3 | 287 mg/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Dalbavancin· 12.3 Pharmacokinetics · dalbavancin table cmax 1000mg · Dalbavancin Pharmaco... | Open |
| 4 | 423 mg/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Dalbavancin· 12.3 Pharmacokinetics · dalbavancin table cmax 1500mg · Dalbavancin Pharmaco... | Open |
| 5 | Observation The expected median maximum plasma concentrations of dalbavancin for pediatric patient age groups ranged between approximately 53% to 73% of that in adult patients (C max , 412 mg/L). | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Dalbavancin· 12.3 Pharmacokinetics · dalbavancin pediatric cmax adult fraction text · The... | Open |
| 6 | Observation In healthy subjects, dalbavancin AUC 0-24h and C max both increased proportionally to dose following single intravenous dalbavancin doses ranging from 140 mg to 1,500 mg, indicating linear pharmacokinetics. | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: intravenous · Dalbavancin· 12.3 Pharmacokinetics · cmax auc dose proportionality text · In healthy subj... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 0.5 hrs 1800 seconds | Comparable | FDA Clinical Pharmacology Review Table 6 manual extraction · human · plasma | Route: intravenous · Dose/window: single 1120 mg dose infused over 30 min · 3 per dose group. | Open |
| 2 | 0.667 hrs 2401.2 seconds | Comparable | FDA Clinical Pharmacology Review Table 6 manual extraction · human · plasma | Route: intravenous · Dose/window: single 140 mg dose infused over 30 min · 3 per dose group. | Open |
| 3 | 0.5 hrs 1800 seconds | Comparable | FDA Clinical Pharmacology Review Table 6 manual extraction · human · plasma | Route: intravenous · Dose/window: single 220 mg dose infused over 30 min · 3 per dose group. | Open |
| 4 | 0.5 hrs 1800 seconds | Comparable | FDA Clinical Pharmacology Review Table 6 manual extraction · human · plasma | Route: intravenous · Dose/window: single 350 mg dose infused over 30 min · 3 per dose group. | Open |
| 5 | 0.5 hrs 1800 seconds | Comparable | FDA Clinical Pharmacology Review Table 6 manual extraction · human · plasma | Route: intravenous · Dose/window: single 500 mg dose infused over 30 min · 3 per dose group. | Open |
| 6 | 0.833 hrs 2998.8 seconds | Comparable | FDA Clinical Pharmacology Review Table 6 manual extraction · human · plasma | Route: intravenous · Dose/window: single 630 mg dose infused over 30 min · 3 per dose group. | Open |
| 7 | 0.5 hrs 1800 seconds | Comparable | FDA Clinical Pharmacology Review Table 6 manual extraction · human · plasma | Route: intravenous · Dose/window: single 840 mg dose infused over 30 min · 3 per dose group. | Open |
Interpretation: Exposure and absorption values should be compared only within matching route, dose, matrix, population, and unit context.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Distribution volume, plasma protein binding, permeability, and BBB penetration evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 0.14 L/kg | Comparable | Volume of distribution at steady state in human after iv administration · human | Route: iv · volume of distribution · Vdss· Volume of distribution at steady state in human after iv a... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | ~ 93 % | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Dalbavancin· 12.3 Pharmacokinetics · dalbavancin plasma protein binding approx · The plas... | Open |
| 2 | 93 % | Comparable | PepTherDia curated product PK field · plasma protein | Route: IV · 84 · Dalbavancin · exact product name match · exact or normalized match | Open |
| 3 | Observation The plasma protein binding of dalbavancin is approximately 93% and is not altered as a function of drug concentration, renal impairment, or hepatic impairment. | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Dalbavancin· 12.3 Pharmacokinetics · dalbavancin binding not altered by impairment text ·... | Open |
PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.
artificial membrane
cell monolayer
cell monolayer
cell monolayer
barrier evidence
Interpretation: Distribution, protein binding, PAMPA, cell-monolayer, and BBB evidence are not interchangeable without matching assay/model context.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Clearance and half-life evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 0.01 mL/min/kg | Comparable | Clearance in human after iv administration · human | Route: iv · clearance · CL· Clearance in human after iv administration · Exact ChEMBL pref name DALBA... | Open |
| 2 | 0.0513 L/h | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Dalbavancin· 12.3 Pharmacokinetics · dalbavancin table clearance single dose · Dalbavanci... | Open |
| 3 | Observation Following a single dose of 500 mg or 1,000 mg dalbavancin, the mean plasma clearance (CL T ) was reduced 11%, 35%, and 47% in subjects with CLcr 50 to 79 mL/min, CLcr 30 to 49 mL/min), and CLcr less than 30 mL/min, respectively, compared to subjects with normal renal function. | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Dalbavancin· 12.3 Pharmacokinetics · dalbavancin renal impairment clearance reduction tex... | Open |
Interpretation: Clearance and half-life require route, matrix, species/population, and time-scale context before comparison.
Reported sequence string matches the current peptide notation.
Reported notation differs, but resolves to the same parent-residue display.
Reported notation does not resolve to the current display sequence.
The identity reference does not expose a sequence string.
No reported sequence notation is available in the current identity references.
No sequence representation
Grouped by reference link, with endpoint scope and reported identity kept visible.
| Reference | Supports | Reported identity | Records |
|---|---|---|---|
Reference link | DistributionExposurePersistence Area Under Curve, Clearance, Max Concentration, Plasma Protein Binding | No reported alias | 0 identity 18 evidence |
Reference link | Exposure Time To Max Concentration | No reported alias | 1 identity 7 evidence |
PubMed 20047912 | Exposure Area Under Curve, Max Concentration | No reported alias | 0 identity 7 evidence |
Reference link | DistributionExposure Bioavailability, Plasma Protein Binding | No reported alias | 0 identity 2 evidence |
PubMed 18426954 | DistributionPersistence Clearance, Volume Of Distribution | No reported alias | 0 identity 2 evidence |
Interpretation: Reference links and reported notations help confirm that measurements point to the same peptide identity or a compatible peptidoform. ADMET interpretation still belongs to the endpoint modules above, where assay/model and condition context are shown with each measurement.
Identity, sequence, profile-level fields, and current release view metadata.
Endpoint-level measurements attached to this peptide, suitable for review or reanalysis.
Nested peptide record for scripted retrieval, including identity and evidence context.
The request returns the same structured peptide record used by this profile. Measurement downloads use the same peptide identifier and public release visibility.
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0020504' \
-H 'accept: application/json' \
-H 'X-Visibility: public_release'Interpretation: Use these files as the reproducible data package for this peptide profile. Cross-peptide comparison still depends on compatible endpoints, assays, species or model systems, route, dose, matrix, and evidence layer.